Venable Partner Paul Strain was quoted in the November 22 American Lawyer Litigation Daily regarding Merck's recent victory in a jury verdict over claims that its osteoporosis drug Fosamax causes jawbone necrosis.
Strain, who represents Merck, argued that Fosamax was thoroughly vetted before gaining U.S. Food & Drug Administration approval, and that the plaintiff's smoking habit, dental problems, and other medications may have contributed to her disease.
Strain, who represents Merck, argued that Fosamax was thoroughly vetted before gaining U.S. Food & Drug Administration approval, and that the plaintiff's smoking habit, dental problems, and other medications may have contributed to her disease.